Why Did Pulse Biosciences, Inc. (NASDAQ:PLSE) Report Wider Net Losses While Completing Pivotal Enrollment Early?

Sonal Goyal

06 November 2026 11:01 PM AEDT

Why Did Pulse Biosciences, Inc. (NASDAQ:PLSE) Report Wider Net Losses While Completing Pivotal Enrollment Early?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Total Revenue was $0.4 million, compared with $0.1 million a year earlier.
GAAP net loss was $23.1 million, compared with $19.4 million in the prior-year quarter.
Enrollment was completed in the U.S. pivotal IDE study in six months, three months ahead of plan.
Interest income is estimated at more than $7.5 million annually at current balances.

Pulse Biosciences, Inc. (NASDAQ:PLSE) reported Business updates and financial results for the third quarter ended September 30, 2026. The company is developing nanosecond pulsed field ablation technology. Total revenue was $0.4 million, compared with $0.1 million in the prior-year period. The GAAP net loss widened to $23.1 million from $19.4 million, while the non-GAAP net loss was $17.5 million compared with $13.5 million.

Pivotal Study and Clinical Progress

Chief Executive Paul LaViolette said the company completed enrollment in its U.S. pivotal IDE study in just six months, three months ahead of plan. The speed of enrollment is a clinical milestone, since pivotal studies are required to support a regulatory submission, and early completion can shorten the path to the next stage of development.

The release also refers to a controlled launch of the Vybrance product, and says the company expects this phase to continue into the fourth quarter of 2027. The controlled launch implies a deliberately limited commercial rollout, so revenue is expected to remain small relative to operating costs during this period.

Losses and Cash Position

The rise in the GAAP net loss to $23.1 million reflects the company's continued Investment in development and commercial preparation. The gap between the GAAP and non-GAAP losses, which the release reconciles, shows that non-cash and other excluded items account for part of the reported loss.

Pulse estimates that its cash, cash equivalents and marketable securities provide more than $7.5 million in annual interest income at current yields. Interest income offsets part of the operating cost base but does not cover it, so the company's losses are expected to continue until revenue scales.

Sector Context and What to Watch

Pulsed field ablation is an emerging area of cardiac and procedural technology in which companies compete on safety, procedure time and clinical evidence. Early-stage device companies typically show losses during pivotal studies and controlled launches, and their results depend on regulatory timing and adoption by physicians.

Final Takeaways

Pulse Biosciences reported a higher GAAP net loss alongside early revenue from a controlled launch and a fast pivotal enrollment. Its interest income partly offsets operating costs, while the path to profitability depends on pivotal outcomes and commercial adoption. The coming quarters will show how the study results and launch revenue develop.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.